![Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease experts](https://ala.associates/wp-content/uploads/2022/04/Screen-Shot-2019-06-21-at-12.52.14-500x222-1.png)
![Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease experts](https://ala.associates/wp-content/uploads/2022/04/Screen-Shot-2019-06-21-at-12.52.14-500x222-1.png)
![Axovant and Yposkesi sign strategic gene therapy development and manufacturing partnership](https://ala.associates/wp-content/uploads/2022/04/GMPsuite_twobioreactors_Photo-courtesy-Yposkesi-e1561019272345-500x250-1.jpg)
Axovant and Yposkesi sign strategic gene therapy development and manufacturing partnership
![Imcyse secures total of €35M in Series B financing round and additional grants](https://ala.associates/wp-content/uploads/2022/04/DSC6577-500x250-1.jpg)
Imcyse secures total of €35M in Series B financing round and additional grants
![Domain Therapeutics appoints Sylvie Ryckebusch to board of directors](https://ala.associates/wp-content/uploads/2022/04/Ryckebusch-Photo1-500x250-1.jpg)
Domain Therapeutics appoints Sylvie Ryckebusch to board of directors
![Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology](https://ala.associates/wp-content/uploads/2022/04/190605-Yposkesi-Genethon_Bioprod_2015_CH_63-min-SMALLER-500x250-1.jpg)
Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology
![Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia](https://ala.associates/wp-content/uploads/2022/04/Minoryx-logo.png)
Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
![Biomunex Pharmaceuticals establishes US subsidiary](https://ala.associates/wp-content/uploads/2022/04/PE-Gerard-e1558960033209-480x250-1.jpg)
Biomunex Pharmaceuticals establishes US subsidiary
![Seventure Partners renews support to Domain Therapeutics and invests €3.5M](https://ala.associates/wp-content/uploads/2022/04/Pascal-NEUVILLE_DOMAIN-Therapeutics_portrait-2-500x250-1.png)
Seventure Partners renews support to Domain Therapeutics and invests €3.5M
![GamaMabs Pharma to present updated results at 2019 ASCO Annual Meeting from the First-In-Human clinical study of murlentamab in advanced gynecological cancers](https://ala.associates/wp-content/uploads/2022/04/Stephane-Degove-GamaMabs-Pharma-500x250-1.jpg)
GamaMabs Pharma to present updated results at 2019 ASCO Annual Meeting from the First-In-Human clinical study of murlentamab in advanced gynecological cancers
![Bionure appoints Dr. Lucia Septien as chief medical offer](https://ala.associates/wp-content/uploads/2022/04/Septien-Lucia-240x250-1.jpg)